



NEOVACS, Leader in Polyclonal Antibody Therapies, assigns Patrick Larcier, as Vice-President Drug Development

Paris, April 25 2005 - NEOVACS, a world-leading company in the field of anti-cytokine and anti-viral active immunization, is pleased to announce the appointment of Patrick Larcier, Pharm.D., MBA, as Vice-President, Drug Development. This new appointment takes place at a time when NEOVACS is accelerating the preclinical and clinical development of several products.

Patrick joined NEOVACS in October 2003 as Director, Clinical Development and Regulatory Affairs.

Patrick gained a 15-year international experience in the pharmaceutical and biotechnology industry and brings to NEOVACS his expertise in clinical development and regulatory strategy. He will be in charge of the pre-clinical and clinical development and operations activities, in relation with experts, and will be responsible for the regulatory strategy with the drug agencies (FDA, EMEA).

Before joining NEOVACS, Patrick was Associate Director Regulatory Affairs, International, within "Biogen" Europe (Biogen-Iddec) since 1999. He worked as Clinical Project Manager within the "Quintiles Emerging Company Institute", "Parexel International" and "SmithKline Beecham International" (GSK), during several years. He began his career as an International Clinical Research Associate at "Abbott Laboratories" in 1990.

Patrick is a Doctor in Pharmacy from the Medical and Pharmacy University of Dijon (France) and holds an MBA from the ESSEC Business School (Paris, France).

Dr Alain Huriez, CEO, said: "I am delighted to have Patrick on board. He brings to NEOVACS a rare international experience in drug development combining in depth clinical and regulatory expertise".

"Joining NEOVACS 18 months ago was a fascinating challenge. I was rapidly convinced about NEOVACS' technology and approaches. Recent results of phase I/II studies with Tat toxoid as well as outcomes of animal models with TNFa-Kinoid,

reinforce my initial feelings : the active specific immunization pathway could really bring new strategies in the treatment of AIDS, cancers and various life-threatening and auto-immune diseases” added Patrick.

About NEOVACS :

NEOVACS, a spin-off company from Pierre et Marie Curie Paris VI University, was founded in 1993 by Professor Daniel Zagury, M.D., one of the best-known French immunologists and AIDS scientists. The company’s research and development has contributed to an impressive number of broad patents and potential drug candidates to treat AIDS, cancer, autoimmune and allergic diseases. NEOVACS is recognized as the pioneer in therapeutic vaccines against human cytokines (Kinoids) and immunosuppressive viral proteins (Toxoids). Currently, humanized monoclonal antibodies are widely used to neutralize cytokines and treat patients with cytokine-related diseases. In contrast to exogenous monoclonal antibody therapies, NEOVACS’ vaccine approach can induce a natural and potent polyclonal antibody response by the patient himself that may last longer, require fewer administrations, and may not encounter common antibody resistance. NEOVACS benefits from an excellent R&D platform, located at two sites within the Pierre et Marie Curie Paris VI University. In 1999, NEOVACS signed a development and licensing agreement with Aventis Pasteur for one of its first promising products, Tat Toxoid, a leading candidate for treatment of HIV infections. Tat Toxoid is being developed in collaboration with Sanofi-Pasteur. Sanofi-Pasteur, the vaccines business of Sanofi-Aventis, is one of the world’s largest vaccine producers.

#

This press release may contain forward-looking statements. As such, they do not guarantee future performance; there are risks and uncertainties. Future scientific, preclinical, clinical, regulatory, manufacturing, financial, commercial, business outcomes may be substantially different from those suggested by the forward-looking statements. The forward-looking statements are effective only as per the date at the top of this press release.

Press contacts

Alizé PR

Caroline Carmagnol

33 (0) 6 64 18 99 59

caroline.carmagnol@wanadoo.fr

NEOVACS -- contact@neovacs.com